Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543128 | 1.00 | CYP2D6 (0.39) | CYP2D6GRIA4ALDH1A1LMNAFFAR4 | |
| SCHEMBL16543127 | 1.00 | CYP2D6 (0.39) | CYP2D6GRIA4ALDH1A1LMNAFFAR4 | |
| SCHEMBL24700592 | 0.75 | KDM1A (0.47) | CYP2D6 | |
| SCHEMBL19700360 | 0.74 | CA12 (0.46) | ALDH1A1LMNA | |
| SCHEMBL6345288 | 0.72 | KDM1A (0.44) | FFAR4TRPV1 | |
| SCHEMBL16535805 | 0.71 | SLC6A2 (0.40) | CYP2D6LMNA | |
| SCHEMBL16535272 | 0.71 | SLC6A2 (0.40) | CYP2D6LMNA | |
| SCHEMBL21232399 | 0.71 | BTK (0.60) | CYP2D6ALDH1A1FFAR4TRPV1 | |
| SCHEMBL21232478 | 0.71 | BTK (0.60) | CYP2D6ALDH1A1FFAR4TRPV1 | |
| SCHEMBL21221593 | 0.71 | TRPV1 (0.52) | CYP2D6FFAR4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | CYP2D6 1509/4885GRIA4 3684/4885ALDH1A1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.